{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:49:29Z","timestamp":1768819769559,"version":"3.49.0"},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,3,24]],"date-time":"2014-03-24T00:00:00Z","timestamp":1395619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content> inhibitors frequently cause significant cutaneous adverse reactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To study the timing, prevalence and response to treatment of skin lesions in patients receiving V\u2010raf murine sarcoma viral oncogene homolog B1 (<jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content>) inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We prospectively studied the cutaneous side\u2010effects of patients with a <jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content> mutant (V600E, V600K, V600R) metastatic malignant melanoma treated with a <jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content> inhibitor. We systematically registered prevalence, timing of onset and response to treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty patients were treated for 2\u201352\u00a0weeks with a <jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content> inhibitor. Eleven patients on vemurafenib (58%) developed cutaneous side\u2010effects and 10 patients (42%) had more than one cutaneous adverse event. Verrucous papillomas were observed in eight patients (42%), after 1\u201312\u00a0weeks. We diagnosed four keratoacanthomas in two patients (11%) after 6\u201310\u00a0weeks and two squamous cell carcinomas in two patients (11%) after 10\u201316\u00a0weeks. Seven patients (37%) developed a hyperkeratotic, folliculocentric eruption after 2\u20138\u00a0weeks, resolving quickly under topical steroids. Four patients (21%) presented a facial erythema, two patients (11%) a seborrhoeic dermatitis\u2010like eczema on the scalp. Three patients (16%) developed cystic lesions after 2\u201311\u00a0weeks. Three patients (16%) presented a hand\u2013foot skin reaction after 4\u20136\u00a0weeks, which was successfully treated with topical steroids and keratolytics. Hyperkeratosis of the nipples was seen in one patient (5%). We observed phototoxic reactions after <jats:styled-content style=\"fixed-case\">UV<\/jats:styled-content> exposure in five patients (26%) and alopecia in two patients (11%) after 8\u201310\u00a0weeks. One patient on dabrafenib developed curly hairs (24\u00a0weeks), keratotic papules (1 and 36\u00a0weeks), a keratoacanthoma (4\u00a0weeks) and a hand\u2013foot skin reaction (31\u00a0weeks).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Multiple cutaneous toxicities were observed in patients under <jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content> inhibitors, mostly well controlled with adequate treatment. We recommend a multidisciplinary approach with regular assessments of the skin by a dermatologist. This allows early identification and adequate treatment to avoid premature discontinuation of a life\u2010prolonging therapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12449","type":"journal-article","created":{"date-parts":[[2014,3,24]],"date-time":"2014-03-24T11:57:02Z","timestamp":1395662222000},"page":"61-68","source":"Crossref","is-referenced-by-count":29,"title":["Cutaneous adverse effects of <scp>BRAF<\/scp> inhibitors in metastatic malignant melanoma, a prospective study in 20 patients."],"prefix":"10.1111","volume":"29","author":[{"given":"L.","family":"Vanneste","sequence":"first","affiliation":[{"name":"Department of Dermatology University Hospitals Leuven Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Wolter","sequence":"additional","affiliation":[{"name":"Department of General Medical Oncology University Hospitals Leuven Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Van den Oord","sequence":"additional","affiliation":[{"name":"Department of Pathology University Hospitals Leuven Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Stas","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology University Hospitals Leuven Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Garmyn","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospitals Leuven Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,3,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60868-X"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/107327481302000404"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2012.01015.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-543-9_16"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70413-8"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12010"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.06.009"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04546.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds292"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.04.008"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt015"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.7680"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.8594"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210093"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12119"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.06.045"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anplas.2012.02.002"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.1660"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12449","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12449","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T22:00:23Z","timestamp":1695506423000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,24]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1111\/jdv.12449"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12449","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,24]]}}}